Time to tumor growth: A model end point and new metric system for oncology clinical trials

Journal of Clinical Oncology

Volumn 31, Issue 17, 2013, Pages 2070-2072

  Maitland, Michael L ^a   Schwartz, Lawrence H ^b   Ratain, Mark J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

CANCER PATIENT; CANCER PROGNOSIS; CANCER RESEARCH; CANCER SURVIVAL; CANCER THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DATA BASE; DISEASE ASSOCIATION; DRUG EFFECT; EDITORIAL; FOLLOW UP; GROWTH CURVE; HUMAN; MEASUREMENT ERROR; METASTATIC COLORECTAL CANCER; METRIC SYSTEM; ORGANIZATION AND MANAGEMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOLID TUMOR; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE;

EID: 84890515847     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.3635     Document Type: Editorial

References (20)

1. Giessen C, Laubender RP, Ankerst DP, et al: Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: Literature-based analysis from 50 randomized first-line trials. Clin Cancer Res 19:225-235, 2013
2. Sidhu R, Rong A, Dahlberg S: Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials. Clin Cancer Res 19:969-976, 2013
3. Stone AM, Bushnell W, Denne J, et al: Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group. Eur J Cancer 47:1763-1771, 2011
4. Amit O, Mannino F, Stone AM, et al: Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis. Eur J Cancer 47:1772-1778, 2011
5. Broglio KR, Berry DA: Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 101:1642-1649, 2009
6. An MW, Mandrekar SJ, Branda ME, et al: Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials. Clin Cancer Res 17:6592-6599, 2011
7. Chibaudel B, Bonnetain F, Shi Q, et al: Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: Evaluation of progression-free survival, duration of disease control, and time to failure of strategy - An Aide et Recherche en Cancérologie Digestive Group Study. J Clin Oncol 29:4199-4204, 2011
8. Claret L, Girard P, Hoff PM, et al: Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol 27:4103-4108, 2009
9. Heun JM, Grothey A, Branda ME, et al: Tumor status at 12 weeks predicts survival in advanced colorectal cancer: Findings from NCCTG N9741. Oncologist 16:859-867, 2011
10. Sharma MR, Karrison TG, Jin Y, et al: Resampling phase III data to assess phase II trial designs and endpoints. Clin Cancer Res 18:2309-2315, 2012
11. Stein WD, Gulley JL, Schlom J, et al: Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: The growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 17:907-917, 2011
12. Wang Y, Sung C, Dartois C, et al: Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther 86:167-174, 2009
13. Claret L, Gupta M, Han K, et al: Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer. J Clin Oncol 31:2110-2114, 2013
14. OECD: Health at a Glance 2011. OECD Indicators 2011. http://www.oecd.org/ health/healthataglance
15. Erasmus JJ, Gladish GW, Broemeling L, et al: Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: Implications for assessment of tumor response. J Clin Oncol 21:2574-2582, 2003
16. Oxnard GR, Zhao B, Sima CS, et al: Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. J Clin Oncol 29:3114-3119, 2011
17. Bogaerts J, Ford R, Sargent D, et al: Individual patient data analysis to assess modifications to the RECIST criteria. Eur J Cancer 45:248-260, 2009
18. Maitland ML, Wu K, Sharma MR, et al: Estimation of renal cell carcinoma treatment effects from disease progression modeling. Clin Pharmacol Ther 93:345-351, 2013
19. Goldmacher GV, Conklin J: The use of tumour volumetrics to assess response to therapy in anticancer clinical trials. Br J Clin Pharmacol 73:846-854, 2012
20. Mozley PD, Schwartz LH, Bendtsen C, et al: Change in lung tumor volume as a biomarker of treatment response: A critical review of the evidence. Ann Oncol 21:1751-1755, 2010